WEALTH September 24, 2026 0 Comments

Cruinn’s Bold Move: Why Snapping Up Katalyst Could Redefine the UK Diagnostics Game Forever

Ever wondered what happens when a powerhouse in Irish diagnostics teams up with a UK-based specialist focused on critical health sectors like mental health, oncology, and pediatrics? Well, buckle up—because Cruinn Diagnostics, already a titan in laboratory equipment and services, just scooped up Katalyst Diagnostics, a dynamic point-of-care diagnostics player entrenched in NHS and specialty clinical circles. This isn’t just another acquisition; it’s a strategic leap that stitches together sterling NHS ties, a savvy local infrastructure, and complementary diagnostic portfolios across the Irish Sea—and it’s poised to reshape the diagnostic landscape in both Ireland and the UK. As someone who’s seen markets shift and strategies evolve, I’m intrigued to watch Cruinn’s bold move to push past €150 million in revenue, building out their footprint with a buy-and-build blueprint that’s bound to stir some serious momentum. Curious to see how this alliance might ripple through the diagnostics world? Dive in and get the full scoop. LEARN MORE

Cruinn Diagnostics, a leading provider of laboratory diagnostic equipment, reagents, consumables and calibrations services, has announced the acquisition of the UK’s Katalyst Diagnostics.

Katalyst is a point-of-service diagnostics business that serves NHS and clinical customers across mental health, oncology, paediatrics and other specialist care settings.

The acquisition is expected to bolster Waterland-backed Cruinn‘s footprint in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions.

It also creates new opportunities to introduce Cruinn products to UK customers, while leveraging Cruinn’s established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland.

The combined group now has more than 100 employees and revenues of more than €50m, and Cruinn plans to make further acquisitions in the UK and Ireland in the coming years.

The transaction forms part of Cruinn’s wider strategy to build a scaled diagnostics distribution group across Ireland and the UK.

Over time, Cruinn will also assess opportunities to expand into selected continental European markets, where complementary acquisitions would add market access, specialist capabilities and further scale.

“Katalyst Diagnostics is a strong strategic fit for Cruinn and gives us a solid platform in the UK market from day one. The business brings established NHS customer relationships, local market knowledge and a differentiated point-of-care diagnostics portfolio that complements our existing capabilities,” said Peter Hussey, CEO at Cruinn Diagnostics.

“Together, we see a clear opportunity to support customers across Ireland and the UK with a broader range of diagnostic solutions, while building a larger and more diversified group.

“This acquisition is an important first step in our UK buy-and-build strategy. Our ambition is to grow the group to €150m in revenue over the coming years by backing strong businesses, investing in people and infrastructure, and expanding the specialist innovative products and services we offer to customers.”

Katalyst Diagnostics will continue to operate under its existing leadership, with Afsheen Khan remaining as managing director.

Waterland Cruinn Diagnostics — (l-r) Waterland’s Laura Dillon and former Cruinn CEO Jack Nolan.

“Cruinn is the right long-term partner for Katalyst Diagnostics. The Group understands our market, shares our focus on service and quality, and has the infrastructure to help us grow,” said Khan.

“I look forward to continuing to lead the UK business as part of the Cruinn Group and to bringing our portfolio to more customers and patients across the UK and Ireland.”

Photo: Peter Hussey. (Pic: Supplied)